Last updated: May 24, 2026
CEQUA (cyclosporine ophthalmic solution, 0.09%) is supplied through a tightly controlled commercial and manufacturing chain typical of branded ophthalmic products: (1) cyclosporine API and film-forming ophthalmic excipients are sourced by approved specialty suppliers under controlled quality systems, (2) formulators produce the sterile, packaged unit in a GMP sterile facility, and (3) distribution and labeler operations are handled under the drug’s marketing authorization holder’s supply contracts.
However, specific supplier names (API manufacturer, sterile fill-finish site, primary packaging component suppliers) are not provided in the available input. Without that source information, a complete and accurate supplier map cannot be produced.
Who supplies CEQUA (cyclosporine ophthalmic solution 0.09%) in the US?
Featured snippet answer: CEQUA is supplied under the brand’s marketing and manufacturing agreements; named third-party supplier entities for API and fill-finish are not specified in the input.
What supplier types matter for CEQUA?
- API supplier: cyclosporine active ingredient (typically supplied under pharma-grade specifications).
- Excipients suppliers: ophthalmic-grade surfactants/solubilizers, tonicity agents, buffers, and viscosity system components.
- Sterile manufacturing and fill-finish: aseptic processing and unit packaging for ophthalmic drops.
- Primary packaging: compatible dropper bottle and closure system designed for ophthalmic sterility and dosing accuracy.
- Secondary packaging and distribution: carton labeling, NDC distribution logistics.
Which companies manufacture CEQUA 0.09% drops (fill-finish and labeling)?
Featured snippet answer: The fill-finish manufacturer(s) and labeler are not identified in the input.
What to verify for CEQUA manufacturing?
- Sterile fill-finish capability for ophthalmic solutions
- Batch release controls for cyclosporine assay, impurities, and preservative content (if applicable)
- Container-closure integrity testing for dropper bottles
- Stability program for marketed shelf life
Do patent and exclusivity issues affect CEQUA supplier availability?
Featured snippet answer: CEQUA supply can be affected by exclusivity and regulatory pathway controls, but those controls do not identify specific suppliers in the input.
How exclusivity can indirectly constrain supply
- Branded commercial arrangements may restrict contract manufacturing capacity through reserved slotting and quality system requirements.
- Generic or BLA-level manufacturing changes only occur after FDA approval and compliance with formulation/process controls.
What is the FDA and Orange Book status of CEQUA that drives supply control?
Featured snippet answer: CEQUA status details are not present in the input, so the exact Orange Book listings and patent expirations cannot be used here.
Why status affects suppliers
- If there are active FDA-listed patents, contract manufacturers may be limited to licensed branded supply chains.
- Patent litigation settlements can include supply and launch timing constraints, affecting who can manufacture or supply competing products.
What generic entry risks exist for CEQUA that could change supplier landscape?
Featured snippet answer: Generic entry risk analysis cannot be completed from the input because the necessary FDA pathway, patent landscape, and litigation records are not provided.
What would typically drive supplier changes
- Paragraph IV filings and court-ordered exclusivity gaps
- Settlement agreements that define design-around formulations/processes
- FDA approval of additional manufacturers under ANDA labeling and quality systems
How does CEQUA’s formulation complexity impact sourcing of excipients and components?
Featured snippet answer: Formulation complexity usually increases the number of qualified suppliers, but specific component supplier identities are not available in the input.
Component-level sourcing pressures
- Ophthalmic-grade excipient specifications (pH window, viscosity, solubilization)
- Compatibility with container-closure materials
- Sterility assurance and bioburden control during compounding
CEQUA supply chain timeline: when do bottlenecks typically appear?
Featured snippet answer: A CEQUA-specific timeline cannot be built from the input.
Typical bottleneck points in ophthalmic supply chains
- API procurement lead times for cyclosporine
- Aseptic fill-finish scheduling and batch release backlogs
- Primary container lot availability and change-control qualification
CEQUA vs Restasis (cyclosporine ophthalmic) suppliers: how do supply networks compare?
Featured snippet answer: A cross-product supplier comparison cannot be done because the input does not provide supplier names for CEQUA or the comparator product.
What to compare in a supplier-network audit
- API sources
- Sterile fill-finish sites
- Packaging/closure suppliers
- Qualified release testing labs
Key Takeaways
- CEQUA supplier identification (API manufacturer, sterile fill-finish manufacturer, packaging suppliers) cannot be stated from the provided input.
- CEQUA supply is governed by standard branded ophthalmic constraints: GMP sterile manufacturing capacity, API and excipient qualification, container-closure compatibility, and FDA-regulated quality controls.
- A complete supplier map requires source-specific disclosures (Orange Book-linked manufacturing disclosures, FDA establishment listings, or credible supply-chain documentation), which are not present in the input.
FAQs
- What is the best way to identify CEQUA contract manufacturing partners?
- How can CEQUA container-closure systems affect supplier qualification and change control?
- What FDA establishment types are most relevant to CEQUA (manufacturing vs testing vs packaging)?
- How do API sourcing constraints for cyclosporine ophthalmic products impact lead times?
- What changes in CEQUA formulation or process would typically require new supplier approvals?
References
- (No cited sources available from the provided input.)
